Did you receive textured
breast implants?

Textured breast implants are linked to causing cancer and you may be entitled to compensation from the manufacturer.

Fill out the form below or call us at
(781) 350-0000 for your free consultation.

Breast Implant lawsuit

Biocell® Textured Breast Implants

If you or someone you know have had textured breast implants, or has been diagnosed with lymphoma or ALCL of the breast, contact us for an immediate free case evaluation. Fil out the form or give us a call at (781) 350-0000.

A new study has found that silicone breast implants with a textured surface are 400-times more likely to cause a rare type of cancer compared to silicone breast implants with a smooth surface.

The study was published in the medical journal JAMA Oncology on January 4 by researchers in the Netherlands.

FDA RECALL

Over 90% of breast implant cancer deaths where the model is known involves Allergan Biocell® textured breast implants


FDA Issues Recall

Also, the FDA requested that Allergan recall all BIOCELL textured breast implants and tissue expanders marketed in the U.S. due to risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a cancer of the immune system. See the FDA report here.

Based on the currently available information, the FDA’s analysis demonstrated that the risk of BIA-ALCL with Allergan BIOCELL textured implants is approximately 6 times the risk of BIA-ALCL with textured implants from other manufacturers marketing in the U.S. and continued distribution of Allergan’s BIOCELL textured breast implants would likely cause serious, adverse health consequences, including death, from BIA-ALCL.

BIA-ALCL is a type of non-Hodgkin’s lymphoma – a cancer of the immune system. BIA-ALCL is typically found in the scar tissue and fluid near the implant. The cancer can spread throughout the body.

Symptoms of BIA-ALCL include persistent swelling or pain near the breast implant.
Through scientific study and investigation, the FDA has confirmed that Allergan Biocell® textured breast implants are linked to cancer.

A total of 573 breast implant BIA-ALCL cases have been recorded worldwide and 481 have involved Allergan Biocell® textured breast implants.
Over 90% of breast implant cancer deaths where the model is known involves Allergan Biocell® textured breast implants.

 

 

Allergan Is Reaching Out To Victims

Allergan is acting unfairly and deceptively by tricking women into signing away and releasing their legal claims.

Please consider not signing anything related to your Allergan Biocell® textured breast implants including forms given to you by your doctor, without consulting a lawyer.

The reason we recommend this extreme precaution is that as part of its warranty claims process, Allergan has asked doctors and their staff to have patients sign seemingly routine paperwork includes a release of claims in the fine print.

While we will challenge the validity of these releases in court, and demand the court order Allergan to stop this heinous practice.

If you have already signed a release or suspect that you may have, please let us know immediately. You may contact us at allerganlawyers@classactions.us or call us at (781) 350-0000.

 

Breast Impant Lawsuit Sources:

Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast
https://jamanetwork.com/journals/jamaoncology/fullarticle/2667737

FDA: Allergan Recalls Natrelle Biocell Textured Breast Implants Due to Risk of BIA-ALCL Cancer
https://www.fda.gov/medical-devices/medical-device-recalls/allergan-recalls-natrelle-biocell-textured-breast-implants-due-risk-bia-alcl-cancer

FDA: The FDA Requests Allergan Voluntarily Recall Natrelle BIOCELL Textured Breast Implants and Tissue Expanders from the Market to Protect Patients: FDA Safety Communication
https://www.fda.gov/medical-devices/safety-communications/fda-requests-allergan-voluntarily-recall-natrelle-biocell-textured-breast-implants-and-tissue

The information provided by class-actions.us is not a substitute for professional medical advice, diagnosis or treatment.
The views and opinions expressed on the site do not necessarily represent those of class-actions.us.